Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonclassical retinoids and lung carcinogenesis.

Konstantin H Dragnev1, W Jeffrey Petty, Yan Ma

  • 1Hematology/Oncology Section, Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, NH 03756, USA. dragnev@dartmouth.edu

Clinical Lung Cancer
|February 8, 2005
PubMed
Summary

Rexinoids, vitamin A derivatives, show promise in cancer therapy by halting cell growth and inducing cell death. Clinical trials are evaluating their effectiveness in treating non-small-cell lung cancer (NSCLC).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Derivation and characterization of ubiquitin-specific protease 18 inhibitors.

JCI insight·2026
Same author

CDK2 Inhibition and Eradication of Aneuploid Cancers: Promise Meets Resistance.

Molecular cancer therapeutics·2026
Same author

Targeting KIFC1 to disrupt centrosome clustering and trigger anaphase catastrophe in small-cell lung cancer.

JCI insight·2026
Same author

Advancing Frontline Therapy in Metastatic NSCLC: Lessons From EVOKE-02 on Antibody-Drug Conjugates-Immunotherapy Combination.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Retinoids, vitamin A derivatives, are known for their anticancer properties, including antiproliferative and proapoptotic effects.
  • Retinoids function by activating nuclear retinoid receptors, influencing gene expression and cellular processes.
  • Rexinoids specifically target the nuclear retinoid X receptors (RXRs), playing a role in cancer treatment strategies.

Purpose of the Study:

  • To investigate the mechanisms of rexinoid action in cancer, particularly in human bronchial epithelial cells.
  • To review the clinical evidence supporting the use of rexinoids in non-small-cell lung cancer (NSCLC) therapy.
  • To explore the potential of rexinoids in combination regimens for enhanced cancer treatment.

Main Methods:

Related Experiment Videos

  • Analysis of rexinoid-induced G1 cell cycle arrest and growth suppression in bronchial epithelial cells.
  • Investigation of proteasome-dependent degradation pathways involved in rexinoid action.
  • Review of clinical trial data on rexinoid monotherapy and combination therapy in NSCLC patients.

    • Main Results:

    • Rexinoid treatment triggered G1 cell cycle arrest and growth suppression in human bronchial epithelial cells.
    • This effect was associated with decreased expression of G1 cyclins via proteasome-dependent degradation.
    • Clinical studies indicated prolonged survival in subsets of NSCLC patients treated with rexinoids.

    Conclusions:

    • Rexinoids demonstrate significant potential as anticancer agents, particularly in NSCLC.
    • Their ability to activate RXR makes them valuable candidates for combination therapies with other targeted agents or chemotherapy.
    • Further randomized phase III trials are crucial to establish the definitive role of rexinoids in lung cancer therapy and chemoprevention.